Compare JBGS & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JBGS | IOVA |
|---|---|---|
| Founded | 2016 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 881.3M |
| IPO Year | 2017 | N/A |
| Metric | JBGS | IOVA |
|---|---|---|
| Price | $16.56 | $2.55 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 1 | 12 |
| Target Price | ★ $18.00 | $10.45 |
| AVG Volume (30 Days) | 485.0K | ★ 12.5M |
| Earning Date | 02-17-2026 | 02-26-2026 |
| Dividend Yield | ★ 4.21% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $501,226,000.00 | $250,425,000.00 |
| Revenue This Year | N/A | $60.71 |
| Revenue Next Year | $1.79 | $59.35 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 175.62 |
| 52 Week Low | $13.28 | $1.64 |
| 52 Week High | $24.30 | $6.16 |
| Indicator | JBGS | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 42.94 | 47.81 |
| Support Level | $16.31 | $2.25 |
| Resistance Level | $16.90 | $2.77 |
| Average True Range (ATR) | 0.44 | 0.22 |
| MACD | -0.03 | -0.03 |
| Stochastic Oscillator | 27.27 | 31.01 |
JBG SMITH Properties is a real estate investment trust based in the United States. It owns, operates, invests in, and develops real estate assets concentrated in amenity-rich, metro-served submarkets in and around Washington, DC. In addition, the company also provides fee-based real estate services to legacy funds through its third-party real estate services business. The operating segments of the company are commercial, multifamily, and third-party asset management and real estate services. It generates maximum revenue from the commercial segment.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.